Biocon banks on pending biosimilar legislation

BANGALORE, India Biocon, a biotechnology company, is turning its focus to biosimilars to market in Europe and the United States, according to business-standard.com.

The company will soon launch two of its new generic versions of biotech molecules, G-CSF (granulocyte colony stimulating factor, which stimulates the bone marrow to produce more white blood cells) and streptokinase (a cardiac drug used against clotting of blood) in the domestic market.

The launch of biosimilars in the U.S. and Europe is planned over the next two to three years, by which time proper laws would evolve for biosimilars in these regions. Biocon is in the process of registering with the regulatory authorities in the developed markets for the launch of Insugen, the company’s version of insulin.